Product Description
Mechanisms of Action: SCN10A Blocker
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Jemincare
Company Location: Asia Pacific
Company Founding Year: 2011
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 3
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Healthy Volunteers|Pain Unspecified
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20242665 |
CTR20242665 | P1 |
Completed |
Pain Unspecified|Healthy Volunteers |
2024-09-15 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20232833 |
CTR20232833 | P1 |
Completed |
Pain Unspecified|Healthy Volunteers |
2024-01-31 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
CTR20240670 |
CTR20240670 | P2 |
Completed |
Unknown |
2025-02-14 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
05/06/2022 |
News Article |
Orion enters into exclusive agreement with Jemincare for novel non-opioid drug candidate for the treatment of pain |